Precision medicine promises the “right drug, right patient” mantra. One piece that sometimes goes missing? A test approved on day one. Jane Li has spent two decades making sure that gap closes on schedule. As senior director of pharma CDx and CRO partnerships at Thermo Fisher Scientific, she has an important role in this complex…
Anima Biotech aims to open the ‘black box’ of disease with large-scale cellular experiments
While many AI companies focus on analyzing existing scientific literature, this approach faces a fundamental challenge: the reliability of the source material itself. “Up to 70% of experiments described in publications cannot be replicated,” notes Yochi Slonim, CEO of Anima Biotech. “You do it once and you publish it. You do it again, it doesn’t…
6 signs AI momentum in drug discovery is building
As pharma giants like Darmstadt, Germany–based Merck KGaA announce new pacts with AI companies, the drug development landscape is witnessing a familiar pattern of emerging tech adoption. AI’s promise of faster, more efficient drug discovery has captured the industry’s imagination, leading Big Pharma to ramp up investment in AI startups and partnerships. Yet, the technology’s…
Astellas’ leadership shares details on $90M South San Francisco Expansion and cell therapy ambitions, AI and robotics
In an exclusive interview with Drug Discovery & Development, Astellas Pharma CEO Naoki Okamura and Chief Scientific Officer Yoshitsugu (Yoshi) Shitaka shared details about its new $90 million, 154,000-square-foot biotech facility in South San Francisco. The new Astellas facility will serve as a central hub for Astellas’ Bay Area employees and be pivotal for the…